The ICD-10 code for sickle cell anemia with vaso-occlusive crisis (D57.0) was introduced in 2010. This code is recommended for the diagnosis of SS-SCD accompanied by pain and crisis. This code is the only one in the ICD-10 code set for VOE (virtual or acquired hemoglobinemia), which is present in double-heterozygous SCD.
ICD-10-CM code for sickle cell anemia with vaso-occlusive crisis
When describing the condition of a sickle cell patient, it is important to use the appropriate ICD-10-CM code. Sickle cell disease is one of the most common inherited blood disorders in the United States. It results in low red blood cell count, repeated infections, and painful episodes. In addition to these symptoms, sickle cell disease is characterized by a deficiency in hemoglobin, which allows red blood cells to carry oxygen. In addition to this, the ICD-10-CM code for sickle cell disease includes anemia.
In order to properly diagnose this condition, an ICD-10-CM code must be assigned for sickle cell anemia with vasa occlusive crisis. However, the code should not be the first diagnosis listed. It should be the second diagnosis listed, after a code for the underlying condition. In this way, it is possible to accurately identify the patient’s condition while coding.
A standardized ICD-10-CM code for sickle-cell anemia with vaso-occlusivity and thrombocytopenia will be more accurate when used for all other sickle-cell anemia subtypes. The D571 diagnosis code, for example, improves sensitivity of SCA diagnoses. It also allows the physician to identify sickle cell anemia cases that are not related to any other disease.
SCD-related hospital stays are highly concentrated in specific metro areas of the U.S. Among patients with SCD, nearly 90 percent were in metro-area hospitals. This is particularly high among Black patients. However, this percentage may not be exactly 100 percent due to missing data. The data on hospital stays for SCD are presented in Supplemental Table 3.
Cost of inpatient stays
The aggregate cost of sickle cell disease-related inpatient stays in 2016 was more than $800 million. Among these, over three-fourths were pain crisis-related. This group was disproportionately younger and Black, with over half of all inpatient stays originating in the emergency department. The study also sought to understand the reasons for the high cost of care and predict the likelihood of readmission.
In 2016 alone, approximately one third of SCD-related inpatient stays involved a single diagnosis. During this time, almost 90 percent of SCD-related stays were accounted for by Black patients. However, the proportions may not add to one hundred due to missing data. In addition, a large proportion of these patients were treated in a subset of U.S. hospitals.
Data on hospital costs are difficult to obtain, but these studies have revealed some interesting trends. While sickle cell disease patients are typically younger than the general population, the average age at admission is older than that of non-sickle-cell-disease patients. The researchers analyzed cost-related factors related to inpatient stays for people with SCD in South Carolina and identified seven trends in the costs. Overall, hospital stays accounted for approximately one-third of SCD patients.
The study found that the majority of SCD-related stays were for patients aged 18-34 years, with a principal SCD diagnosis or pain crisis. In this age group, a primary diagnosis of SCD was most common, but SCD-related pain crisis was the most prevalent. This group of patients was responsible for nearly half of the total number of SCD-related inpatient stays, with a range of 68.8 to eighty percent and 22.2-four percent respectively.
Cost of outpatient stays
The cost of outpatient stays for patients with sickle cell disease was almost $59 million in 2016 alone. While the majority of patients used only one or two hospitals, a small group utilized more than four hospitals. The most expensive hospital stays involved patients between the ages of 18 and 34. The majority of these visits started in the emergency department. This article examines the factors that contributed to the cost of sickle cell care.
The study included only patients with confirmed sickle cell disease (SCD). It did not include hospitalizations for other procedures or in pregnancy. However, the researchers did note that the study did not include costs for transfer hospitalizations. This may be due to the limited availability of information about the pain crisis in sickle cell patients. The only cure for SCD is a stem cell transplant.
A study of the cost of outpatient stays in patients with SCD found that a majority of these patients stayed in the hospital for at least one time during the year. The study also found that the average hospital stay was 4.5 days, and that the mean cost per patient was $7290. Physician and hospitalization visits accounted for an additional $5616, making the total cost of care $19,194. Outpatient hospital stays, meanwhile, totaled $305 and $169, respectively.
The data also revealed that a majority of SCD-related hospital stays involved SCD as the primary diagnosis. The other three-quarters of these patients had SCD as the primary diagnosis, indicating that one-third or more of these patients also had a pain crisis. Compared to these patients, the majority of SCD-related hospital stays were for patients aged 18 to 34.
Cost of emergency department visits
Emergency department visits for sickle cell disease were a big expense last year, with nearly 130,000 people seeking treatment. Of these, over three-fourths of the stays involved a pain crisis. Of those who received treatment, 50 percent were children and 90 percent were African American. Emergency department visits were also common among older adults, and those with SCD were most likely to seek treatment in the ED.
In the U.S., emergency department visits for SCD were concentrated in a small number of metro hospitals, and black patients accounted for nearly 90 percent of these visits. Data on a subset of hospitals are provided in Supplemental Table 6.
The study also evaluated healthcare costs for patients with SCD. While almost half of these visits were for patients with SCD, over ninety percent occurred in patients living in lower-income communities. By contrast, less than one-third of these visits were for patients without SCD. The study found that costs for these visits were significantly higher than those for patients with other diseases. In the same study, over 80 percent of those with SCD received care in an emergency department, and the cost of their hospital stay was higher than that of other diseases.
The costs of SCD hospitalizations were over $900 million in 2018 alone. According to Blinder et al., cost of SCD treatment and complications were associated with age, and the quarterly costs ranged between $11,913 and $11,957, depending on the patient’s age. Overall, the costs per SCD patient were estimated at approximately $780,500 a year.